Spyre Therapeutics Inc. share price logo

Spyre Therapeutics Inc. Share Price

NASDAQ: SYRE

Mid Cap

$63.91

+0.64

(+1.01%)

as on

Spyre Therapeutics Inc. Stock Performance

as on April 15, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $60.75
    $67.68
    downward going graph

    4.94%

    Downside

    5.90%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $12.04
    $75.00
    downward going graph

    81.16%

    Downside

    17.35%

    Upside

    downward going graph

Spyre Therapeutics Inc. share price movements today

Previous Close
$63.27
Open
$66.16
Volume
1.7M
Day's Low - High
$60.75 - $67.68
52 Week Low - High
$12.04 - $75.00

Spyre Therapeutics Inc. Historical Returns

1 Month Return
+ 58.61 %
3 Month Return
+ 90.8 %
1 Year Return
+ 385.94 %
3 Year Return
0 %
5 Year Return
0 %

Spyre Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Spyre Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.0B

EPS (TTM)

-2.8386

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-1.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-207.8M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-25.17%

Spyre Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Spyre Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$4.0BNANA0.00%
BUY$42.7B140.76%138.848.45%
BUY$111.0B102.67%28.532.94%
NA$35.6BNA124.865.37%
BUY$79.2B55.14%18.0531.41%

Stock Returns calculator for Spyre Therapeutics Inc. Stock including INR - Dollar returns

The Spyre Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Spyre Therapeutics Inc. investment value today

Current value as on today

₹5,30,983

Returns

₹4,30,983

(+430.98%)

Returns from Spyre Therapeutics Inc. Stock

₹3,90,860 (+390.86%)

Dollar Impact

₹40,122 (+40.12%)

Analyst Recommendation on Spyre Therapeutics Inc. Stock

Based on 13 analysts

BUY

92.31%

Buy

7.69%

Hold

0.00%

Sell

Based on 13 analysts, 92.31% of analysts recommend a 'BUY' rating for Spyre Therapeutics Inc.. Average target price of $64.36

Spyre Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Spyre Therapeutics Inc..

What analysts predicted

0.7%UPSIDE

Target Price

$64.36

Current Price

$63.91

Analyzed by

13 Analysts

Target

$64.36

Spyre Therapeutics Inc. target price $64.36, a slight upside of 0.7% compared to current price of $63.91. According to 13 analysts rating.

Spyre Therapeutics Inc. Stock’s Investor Sentiment and Interest

Search interest for Spyre Therapeutics Inc. Stock has decreased by -27% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-27% versus previous 30 day period

Spyre Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
1
-
-
-
-
-
-
-
90
Gross Profit
-
0
-
-
-
-
-
-
-45
45
Operating Income
-18
-45
-47
-44
-55
-61
-53
-41
-56
-57
EBITDA
-33
-47
-47
-44
-55
-61
-53
-51
-11
-62
Interest Expense
-
-
-
-
-
21
-
-
-
-
Depreciation
-
0
-
-
-
-
-
-
-
-
Income Before Tax
-40
-63
-43
-38
-69
-56
-44
-36
-11
-62
Income Tax Expense
0
-5
0
-
0
0
0
-
-
0
Net Income
-40
-63
-43
-38
-69
-56
-44
-36
-11
-62
Net Profit Margin
0.00%
-6063.34%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
-69.10%

Spyre Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4
5
3
-
-
18
2
0
0
-
Gross Profit
4
5
3
0
-1
18
2
0
0
-171
Operating Income
-21
-27
-45
-80
-81
-65
-84
-242
-208
-209
EBITDA
-21
-27
-45
-77
-79
-64
-82
-242
-207
-209
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
0
0
1
1
0
-
-
Income Before Tax
-21
-27
-44
-78
-80
-65
-83
-338
-207
-155
Income Tax Expense
-
-
-
-
0
0
0
0
0
0
Net Income
-21
-27
-44
-78
-80
-65
-83
-338
-208
-155
Net Profit Margin
-468.84%
-523.27%
-1140.64%
0.00%
0.00%
-351.14%
-3598.75%
-38238.15%
-23478.33%
0.00%

Spyre Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-63
-43
-38
-69
-56
-44
-36
-11
-51
Operating Cash Flow
-31
-28
-62
-29
-37
-40
-46
-37
-44
Investing Cash Flow
-35
-104
-120
42
-170
0
78
24
-247
Financing Cash Flow
163
172
0
12
225
0
0
-4
312
Change in Cash
97
38
-182
26
17
-40
33
-16
20

Spyre Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-27
-44
-78
-80
-65
-83
-338
-208
-155
Operating Cash Flow
-24
-32
-65
-75
-53
-80
-99
-157
-169
Investing Cash Flow
-22
-15
-1
-7
-22
57
-
-353
-143
Financing Cash Flow
12
57
65
154
1
42
361
410
309
Change in Cash
-34
9
-3
71
-74
19
152
-99
-3

Spyre Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 13 October

    Tue, 01:31 AM

    -

    Spyre Therapeutics announces proposed public offering of common stock and pre-funded warrants.

    Tue, 06:38 AM

    -

    Spyre Therapeutics prices public offering at $18.50 per share, aiming to raise $275 million.

Insights on Spyre Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 5 quarters, 168.0K → 90.49M (in $), with an average increase of 54.8% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, SYRE stock has moved up by 1587.2%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, SYRE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, SYRE has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -11.18M → -62.53M (in $), with an average decrease of 459.2% per quarter

About Spyre Therapeutics Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
OrganisationSpyre Therapeutics Inc.
HeadquartersBuilding 23, Waltham, MA, United States, 02453
IndustryBiotechnology
CEODr. Cameron Turtle DPHIL, Ph.D.
E-voting on sharesClick here to vote

Key Management of Spyre Therapeutics Inc.

Name

Title

Ms. Melissa Cooper

Senior Vice President of People

Dr. Cameron Turtle DPHIL, Ph.D.

CEO & Director

Mr. Scott L. Burrows

Chief Financial Officer

Dr. Sheldon Sloan M.B.E., M.D.

Chief Medical Officer

Dr. Justin LaFountaine Ph.D.

Senior Vice President of Corporate Development

Mr. James Myers

Vice President of Quality & Compliance

Dr. Janet Gunzner-Toste M.B.A., Ph.D.

Senior Vice President of Operations

Mr. Brian Connolly

Chief Technical Officer

Mr. Eric McIntyre

Vice President of Finance & Investor Relations

Ms. Heidy Abreu King-Jones J.D., L.L.M.

Chief Legal Officer & Corporate Secretary

FAQs

What is Spyre Therapeutics Inc. share price today?

Spyre Therapeutics Inc. share price today is $63.91 as on at the close of the market. Spyre Therapeutics Inc. share today touched a day high of $67.68 and a low of $60.75.

What is the 52 week high and 52 week low for Spyre Therapeutics Inc. share?

Spyre Therapeutics Inc. share touched a 52 week high of $75 on and a 52 week low of $12.04 on . Spyre Therapeutics Inc. stock price today i.e. is closed at $63.91,which is 14.79% down from its 52 week high and 430.81% up from its 52 week low.

What is Spyre Therapeutics Inc.'s market capitalisation today?

Spyre Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Spyre Therapeutics Inc. Stock (SYRE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Spyre Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Spyre Therapeutics Inc. Shares that will get you 0.0235 shares as per Spyre Therapeutics Inc. share price of $63.91 per share as on April 15, 2026 at 1:29 am IST.

What is the minimum amount required to buy Spyre Therapeutics Inc. Stock (SYRE) from India?

Indian investors can start investing in Spyre Therapeutics Inc. (SYRE) shares with as little as ₹93.082 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹930.82 in Spyre Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Spyre Therapeutics Inc. share’s latest price of $63.91 as on April 15, 2026 at 1:29 am IST, you will get 0.1565 shares of Spyre Therapeutics Inc.. Learn more about fractional shares .